Panel’s opinion could pave way for full regulatory approval next month for treatment of disease that affects 6.5m AmericansA panel that advises the Food and Drug Administration agreed that a new drug to treat Alzheimer’s disease was beneficial for slowing cognitive decline, paving the way for full regulatory approval next month.Earlier this year…
Read More
About The Author
